Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide - PubMed (original) (raw)

Clinical Trial

Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide

J J Lewis et al. Int J Cancer. 2000.

Abstract

The lack of reproducible, quantitative assays for T-cell responses has been a limitation in the development of cancer vaccines to elicit T-cell immunity. We utilized the Elispot assay, which allows a quantitative and functional assessment of T cells directed against specific peptides after only brief in vitro incubations. CD8(+) T-cell reactivity was determined with an interferon (IFN)-gamma Elispot assay detecting T cells at the single cell level that secrete IFN-gamma. We studied both healthy individuals and patients with melanoma. Healthy HLA-A*0201-positive individuals showed a similar mean frequency of CD8(+) cells recognizing a tyrosinase peptide, YMDGTMSQV, when compared with melanoma patients prior to immunization. The frequencies of CD8(+) cells recognizing the tyrosinase peptide remained relatively constant over time in healthy individuals. Nine HLA-A*0201-positive patients with stage IV metastatic melanoma were immunized intradermally with the tyrosinase peptide together with the immune adjuvant QS-21 in a peptide dose escalation study with 3 patients per dose group. Two patients demonstrated a significant increase in the frequency of CD8(+) cells recognizing the tyrosinase peptide during the course of immunization, from approx. 1/16,000 CD8(+) T cells to approx. 1/4,000 in the first patient and from approx. 1/14,000 to approx. 1/2,000 in the second patient. These results demonstrate that modest expansion of peptide-specific CD8(+) T cells can be generated in vivo by immunization with peptide plus QS-21 in at least a subset of patients with melanoma.

PubMed Disclaimer

Cited by

Peptide Dose and/or Structure in Vaccines as a Determinant of T Cell Responses.
Leggatt GR. Leggatt GR. Vaccines (Basel). 2014 Jul 2;2(3):537-48. doi: 10.3390/vaccines2030537. Vaccines (Basel). 2014. PMID: 26344744 Free PMC article. Review.
CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice.
Saha A, Baral RN, Chatterjee SK, Mohanty K, Pal S, Foon KA, Primus FJ, Krieg AM, Weiner GJ, Bhattacharya-Chatterjee M. Saha A, et al. Cancer Immunol Immunother. 2006 May;55(5):515-27. doi: 10.1007/s00262-005-0009-6. Epub 2005 Jul 26. Cancer Immunol Immunother. 2006. PMID: 16044253 Free PMC article.
Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide.
Tangri S, Ishioka GY, Huang X, Sidney J, Southwood S, Fikes J, Sette A. Tangri S, et al. J Exp Med. 2001 Sep 17;194(6):833-46. doi: 10.1084/jem.194.6.833. J Exp Med. 2001. PMID: 11560998 Free PMC article.
Immunotherapy of melanoma.
Smith C, Cerundolo V. Smith C, et al. Immunology. 2001 Sep;104(1):1-7. doi: 10.1046/j.1365-2567.2001.01297.x. Immunology. 2001. PMID: 11576213 Free PMC article. Review. No abstract available.

Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide - PubMed (original) (raw)